The closing price of Regulus Therapeutics Inc (NASDAQ: RGLS) was $2.72 for the day, down -2.86% from the previous closing price of $2.80. In other words, the price has decreased by -$0.0800 from its previous closing price. On the day, 826404 shares were traded.
Ratios:
Our analysis of RGLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 2.96. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 18, 2024, initiated with a Outperform rating and assigned the stock a target price of $6.
On March 28, 2018, B. Riley FBR Inc. started tracking the stock assigning a Neutral rating and target price of $1.
On January 05, 2018, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $2.Leerink Partners initiated its Outperform rating on January 05, 2018, with a $2 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 18 ’24 when Hagan Joseph P sold 14,580 shares for $1.19 per share. The transaction valued at 17,359 led to the insider holds 57,112 shares of the business.
CALSADA CRISPINA sold 5,468 shares of RGLS for $6,510 on Jan 18 ’24. The Chief Financial Officer now owns 5,782 shares after completing the transaction at $1.19 per share. On Jan 18 ’24, another insider, Aker Christopher Ray, who serves as the Sr. VP & General Counsel of the company, sold 5,468 shares for $1.19 each. As a result, the insider received 6,510 and left with 10,056 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGLS now has a Market Capitalization of 179.37M and an Enterprise Value of 158.00M.
Stock Price History:
Over the past 52 weeks, RGLS has reached a high of $3.79, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 1.8093, while the 200-Day Moving Average is calculated to be 1.4852.
Shares Statistics:
RGLS traded an average of 3.04M shares per day over the past three months and 915.85k shares per day over the past ten days. A total of 65.47M shares are outstanding, with a floating share count of 57.42M. Insiders hold about 12.29% of the company’s shares, while institutions hold 23.55% stake in the company. Shares short for RGLS as of Mar 15, 2024 were 5.13M with a Short Ratio of 1.68, compared to 97k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.84% and a Short% of Float of 8.42%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.44, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.42 and -$0.57 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.61, with 3 analysts recommending between -$0.47 and -$0.75.
